TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37509587
Drug: GABA/GAD65-alum treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA/GAD65-alum treatment
Study: 37510953
Drug: Single-strain probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-strain probiotic formulations
Study: 37511562
Drug: CAR-T therapy
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T therapy (Yescarta™)
Study: 37513677
Drug: MFGM-enriched milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFGM-enriched milk beverage (MEB) (2.3 g/d milk phospholipids)
Study: 37515050
Drug: Single booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single booster dose
Study: 37515194
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of probenecid every 12 h for five days
Study: 37515194
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of probenecid every 12 h for five days
Study: 37515459
Drug: Normobaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric oxygen (NBO) therapy within 6 hours of symptom onset
Study: 37515459
Drug: Normobaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric oxygen (NBO) therapy
Study: 37516125
Drug: Atogepant 30
Normalized name: atogepant 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant 30 mg twice a day
Study: 38364831
Drug: Atogepant 60
Normalized name: atogepant 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant 60 mg once a day
Study: 37516163
Drug: CBT-I (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-I (Cognitive Behavioral Therapy for Insomnia)
Study: 37516163
Drug: CBT-D (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-D (Cognitive Behavioral Therapy for Depression)
Study: 37516163
Drug: CBT-I +
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-I + D (sequential intervention)
Study: 37516163
Drug: CBT-D +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-D + I (sequential intervention)
Study: 37516818
Drug: EGFR TKI
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR TKI treatment
Study: 37516867
Drug: UCPVax vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCPVax vaccine at 0.5 mg subcutaneously combined with atezolizumab (1200 mg IV infusion) and bevacizumab (15 mg/kg IV infusion) every 3 weeks.
Study: 37516867
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg IV infusion) and bevacizumab (15 mg/kg IV infusion) every 3 weeks.
Study: 37517422
Drug: OVX836 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: OVX836 180 μg
Study: 37517422
Drug: OVX836 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: OVX836 300 μg
Study: 37517422
Drug: OVX836 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: OVX836 480 μg
Study: 37517579
Drug: Stent placement
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stent placement with best medical therapy (BMT)
Study: 37517875
Drug: RRMM treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRMM treatments
Study: 37518058
Drug: Supplemental enteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental enteral protein (1.2 g/kg/day) starting from ICU day 5 until ICU discharge or ICU day 90
Study: 37518058
Drug: Standard enteral
Normalized name: Standard enteral formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard enteral nutrition formula (0.8-1.2 g/kg/day) without supplemental protein
Study: 37518058
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups receive primary enteral formula with a maximum protein of 1.2 g/kg/day
Study: 37518060
Drug: Apatinib 500
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500 mg QD on days 1-4; Gefitinib 250 mg QD on days 5-15, combined with Apatinib 500 mg QD on days 12-15.
Study: 37518076
Drug: High-dose docosahexaenoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose docosahexaenoic acid (DHA) enteral supplementation during the neonatal period
Study: 37518076
Drug: High-dose DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DHA enteral supplementation
Study: 37518082
Drug: Optokinetic stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optokinetic stimulation (OKS) - 2 weekly sessions for 10 weeks using virtual reality glasses to project OKS at a preset speed.
Study: 37518082
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment - virtual reality video without OKS.
Study: 37518089
Drug: Colistin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin administered as colistin methanesulfonate (CMS) intravenously at standard dosing.
Study: 37518975
Drug: Fecal elastase-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal elastase-1 (FE-1) levels >500 µg/g
Study: 37519971
Drug: Regenerative endodontic
Normalized name: Regener-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regenerative endodontic therapy (RET) with modified triple antibiotic paste (mTAP)
Study: 37519971
Drug: Regenerative endodontic
Normalized name: Regener-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regenerative endodontic therapy (RET) with Metapex™
Study: 37520411
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg IV sotrovimab
Study: 37521410
Drug: Hydrogen-rich coral
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen-rich coral calcium (HRCC) capsules (low, medium, and high doses)
Study: 37521410
Drug: Hydrogen-rich coral
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen-rich coral calcium (HRCC) capsules
Study: 37522330
Drug: Existing phototherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Existing phototherapy treatment
Study: 37522415
Drug: Oxytocin 240
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin 240 IU inhaled
Study: 37522415
Drug: Oxytocin 5
Normalized name: oxytocin 5 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin 5 IU intravenous
Study: 37522415
Drug: Oxytocin 10
Normalized name: oxytocin 10 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin 10 IU intramuscular
Study: 37522415
Drug: Blood collected
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood collected into lithium heparin (LH) tubes
Study: 37522479
Drug: Modified rIX-FP
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified rIX-FP regimen at 40 IU/kg twice/week
Study: 37523661
Drug: Lenvatinib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib (20 mg orally once daily) plus Pembrolizumab (200 mg intravenously every 3 weeks)
Study: 37523661
Drug: Chemotherapy (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (doxorubicin or paclitaxel)
Study: 37524096
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg oral daily for 54 weeks
Study: 37524201
Drug: AZD7442 (tixagevimab/cilgavimab)
Normalized name: tixagevimab
DrugBank: AZD7442 (DB15787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7442 (tixagevimab/cilgavimab) 300 or 600 mg intramuscularly or 300 or 1000 mg intravenously
Study: 37524230
Drug: RG6346 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG6346 at 1.5 mg/kg
Study: 37524230
Drug: RG6346 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG6346 at 3.0 mg/kg
Study: 37524230
Drug: RG6346 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG6346 at 6.0 mg/kg
Study: 37525125
Drug: Virtual group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual group-based acceptance and commitment therapy (n=35)
Study: 37525207
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted manual-assisted problem-solving intervention (CMAP) plus enhanced treatment as usual (E-TAU)
Study: 37525207
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (E-TAU)
Study: 37525278
Drug: Autologous leukocyte-
Normalized name: interferon alfa-3n,human leukocyte derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous leukocyte- and platelet-rich fibrin (L-PRF) membranes
Study: 37525298
Drug: Treated participants
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treated participants (n=471, 62%) who self-reported accessing BN/BED treatment at some point in their lives
Study: 37525298
Drug: Untreated participants
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated participants (n=291, 38%) who never accessed treatment
Study: 37525298
Drug: Individuals with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals with a history of inpatient or residential treatment
Study: 37525298
Drug: Individuals with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals with outpatient treatment
Study: 37525369
Drug: rabbit antithymocyte
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabbit antithymocyte globulin (2 × 1.5 mg/kg, postoperative days 0 and 1) and infliximab (5 mg/kg, postoperative day 2) followed by mycophenolate-free tacrolimus-based immunosuppression for 12 mo
Study: 37525414
Drug: Laparoscopic-assisted transversus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic-assisted transversus abdominis plane block (L-TAPB)
Study: 37525559
Drug: Supervised concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised concurrent exercise training program
Study: 37525914
Drug: GJA4 variants
Normalized name: Carduus Marianus
DrugBank: Milk thistle (DB14375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GJA4 variants (homozygous G variant, n = 84; 73%)
Study: 37526149
Drug: Datopotamab deruxtecan
Normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Datopotamab deruxtecan (Dato-DXd) 6 mg/kg iv. every 3 weeks
Study: 37526436
Drug: Multiple benzodiazepine
Normalized name: 1,2-Benzodiazepine
DrugBank: 1,2-Benzodiazepine (DB12537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple benzodiazepine receptor agonists
Study: 37526856
Drug: Medium-dose MF/IND/GLY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose MF/IND/GLY
Study: 37526856
Drug: High-dose ICS/LABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ICS/LABA
Study: 37526936
Drug: Orteronel 300
Normalized name: Orteronel
DrugBank: Orteronel (DB12066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orteronel 300 mg orally twice daily
Study: 37526936
Drug: Bicalutamide 50
Normalized name: bicalutamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 50 mg orally daily
Study: 37526937
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control (weekly health education telephone calls)
Study: 37527479
Drug: Symptom remission
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom remission without antipsychotic medication
Study: 37527726
Drug: Autologous cord
Normalized name: Autologous cord blood
DrugBank: Autologous cord blood (DB17926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous cord blood mononucleated cells (CBMNCs) delivered via intracoronary infusion during Norwood procedure, 4 doses of 15 mL each, without prior cryopreservation.
Study: 37527730
Drug: Best Practices
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best Practices plus Financial Incentives and Nicotine Replacement Therapy (BP + FI + NRT)
Study: 37527890
Drug: Peer-supported, WhatsApp-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-supported, WhatsApp-assisted lifestyle modification intervention delivered by a trained nutritionist for 1 year (3 days after baseline and then monthly).
Study: 37527898
Drug: Bedtime use
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime use of antihypertensives
Study: 37527898
Drug: Morning use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning use of antihypertensives
Study: 37528405
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (OAC) therapy including non-vitamin K antagonist oral anticoagulants (NOACs)
Study: 37528410
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality (VR) exposure therapy
Study: 37528500
Drug: Upadacitinib 30
Normalized name: upadacitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 30 mg (rescue treatment)
Study: 37528500
Drug: Upadacitinib (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib (7.5 mg, 15 mg, 30 mg)
Study: 37529157
Drug: SHR-1802 (anti-LAG-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1802 (anti-LAG-3 monoclonal antibody) administered once every 21-day cycle, with doses escalating from 0.3 to 10 mg/kg
Study: 37529919
Drug: Palbociclib with
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib with aromatase inhibitors
Study: 37530622
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg IV every 2 weeks until progression or unacceptable toxicity (Cohort A, B, C)
Study: 37530622
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg IV every 2 weeks until progression or unacceptable toxicity (Cohort C)
Study: 37530627
Drug: JAKi monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAKi monotherapy (ruxolitinib, fedratinib, momelotinib)
Study: 37530855
Drug: Anterior implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior implant treatment
Study: 37530892
Drug: Furlow palatoplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furlow palatoplasty with buccal myomucosal flap (FPBF)
Study: 37531083
Drug: LY3405105 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3405105 monotherapy (20 mg QD)
Study: 37531083
Drug: LY3405105 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3405105 monotherapy (1-2 mg orally, escalated)
Study: 37531083
Drug: LY3405105 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3405105 monotherapy (QD vs TIW dosing)
Study: 37531083
Drug: LY3405105 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3405105 monotherapy (≥15 mg QD)
Study: 37531130
Drug: Moderate-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity statin with ezetimibe (rosuvastatin, 10 mg with ezetimibe, 10 mg)
Study: 37531657
Drug: Dose 4
Normalized name: Isordil Titradose 40mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 4 of vaccine at previously received antigen levels (100 or 200 μg)
Study: 37531986
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of normal saline
Study: 37531986
Drug: No administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No administration
Study: 37532066
Drug: Three exercise
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three exercise sessions per week in adjunct to diet-induced weight loss
Study: 37532066
Drug: Six exercise
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six exercise sessions per week in adjunct to diet-induced weight loss
Study: 37532157
Drug: Parenteral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Parenteral treprostinil
Study: 37532250
Drug: Prednisolone eyedrops
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone eyedrops (tapering schedule)
Study: 37532611
Drug: Tetravalent live
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent live attenuated dengue vaccine
Study: 37532622
Drug: SYN120 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN120 (100 mg/day)
Study: 37532933
Drug: Next-generation probiotics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Next-generation probiotics, specific details on dosage and duration not available
Study: 37532985
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of antipsychotics
Study: 37533033
Drug: L-carnitine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (1 g of LC-L-tartrate and 3 g of leucine per day)
Study: 37533033
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 g of leucine per day)
Study: 37533058
Drug: tDCS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDCS treatment (active)
Study: 37533058
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS treatment (placebo)
Study: 37533228
Drug: Long-term temozolomide
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term temozolomide (TMZ) treatment
Study: 37533380
Drug: Trazpiroben (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazpiroben (all doses combined)
Study: 37533418
Drug: Awareness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awareness of antibody response
Study: 37533419
Drug: All booster
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All booster formulations
Study: 37533588
Drug: Ketamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine treatment (serial intravenous infusions)
Study: 37533657
Drug: High-intensity laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity laser therapy (HILT) + stretching exercise
Study: 37533657
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) + stretching exercise
Study: 37533867
Drug: rBCG-N-hRSV vaccine
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: rBCG-N-hRSV vaccine
Study: 37534543
Drug: Fostamatinib (a
Normalized name: fostamatinib (as disodium hexahydrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib (a SYK inhibitor)
Study: 37534999
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy using nanovesicles
Study: 37534996
Drug: gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine plus nab-paclitaxel in combination with indoximod
Study: 37535240
Drug: Avalglucosidase alfa
Normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Avalglucosidase alfa (AVAL) at a dosage of 20 mg/kg
Study: 37535240
Drug: Avalglucosidase alfa
Normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Avalglucosidase alfa (AVAL) at a dosage of 40 mg/kg
Study: 37535357
Drug: Telephone-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based cognitive behavioral therapy (tele-CBT) consisting of 6 weekly 1-hour sessions and a booster session 1 month later.
Study: 37535377
Drug: Camrelizumab plus
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab plus chemotherapy (200 mg camrelizumab, nab-paclitaxel 130 mg/m2, cisplatin 75 mg/m2 or carboplatin AUC 5 or nedaplatin 100 mg/m2)
Study: 37535382
Drug: Aflibercept, 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept, 8 mg (70 μL)
Study: 37535382
Drug: Aflibercept, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept, 2 mg (50 μL)
Study: 37535388
Drug: Standard second-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard second-line chemotherapy
Study: 37535416
Drug: Machine Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine Learning Clinical Decision Support (ML-CDS) tool
Study: 37535416
Drug: ML-CDS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ML-CDS intervention
Study: 37535416
Drug: ML-CDS tool
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML-CDS tool
Study: 37535419
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of melatonin
Study: 37535419
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of melatonin
Study: 37535521
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ABC-I)
Study: 37535555
Drug: Mindfulness-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based therapy (MBT) ROC-T
Study: 37535555
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) ROC-T
Study: 37535618
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of remimazolam tosylate and propofol (R+P group)
Study: 37535775
Drug: All interventions
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All interventions (Ozone, Steroid, Pulsed Radiofrequency)